Mutations in epigenetic regulators such as TET2, IDH1 and IDH2 are much less prevalent compared to adult AML, characterizing only 1–2% of pediatric patients [27], while signaling mutations such as NRAS, KRAS, CBL, GATA2, SETD2 and PTPN11 are more common in younger patients. Here, NRAS is linked to acute myeloid leukemia.